WE'RE COMMITTED TO DEVELOPING TREATMENTS THAT WILL BETTER THE LIVES OF PEOPLE WITH INFLAMMATORY DISEASES

WE'RE COMMITTED TO DEVELOPING TREATMENTS THAT WILL BETTER THE LIVES OF PEOPLE WITH INFLAMMATORY DISEASES

Mission &    Core Values |

Acquist is a team of dedicated and high-energy individuals who appreciate a challenging entrepreneurial environment and who contribute daily to our company objectives.  We are committed to aggressively leveraging our expertise in inflammation and drug discovery, development, and commercialization

Acquist is a biopharmaceutical company focused on the identification, development and commercialization of drugs that alter the inflammatory process.  Our strategy is to maximize value through excellence in performance and innovation while maintaining the highest standards of integrity and leadership.  Acquist is committed to developing innovative products to better the lives of people with chronic inflammatory disorders. The Company’s lead programs are in NASH and chronic gout.

Vision |

Acquist is focused on the identification, development and commercialization of drugs that regulate the process of inflammation. Aquist is committed to developing innovative products to better the lives of people with chronic inflammatory disorders. The Company’s lead programs are in NASH and chronic gout.

Core Expertise |

The principals of our Company have extensive experience in discovering new drugs, optimizing lead compounds, pulling these leads to IND-ready FDA submissions and into clinical development from Phase 0 through Phase 4. Generally, we expect to take our candidates through completion of randomized trials and to seek partners to fully realize commercial opportunities.

Core Interest |

We focus on identifying drug prototypes or compound families that have already been tested in patients but have not been targeted at inflammatory diseases. These conditions typically require extended treatment, and prior demonstration of safety in patients is a paramount consideration. We then narrow metabolic pathways to those that offer multiple “drugable” targets for our discovery chemistry program. Such “clinical proof-of-concept” reduces risk, identifies clinical markets of interest, and clarifies pathways for regulatory approval.

Copyright © 2019 Acquist Theraputics, Inc.® 

Made with  by CBE Studio